GGrantIndex
← Leaderboards

Monique Marie Hedderson

University Of Pittsburgh At Pittsburgh

$17,343,525
Attributed
$39,321,331
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $18.5M · FY201025
$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$82,105,987 · 11

By mechanism

U19$42,784,656 · 1
R01$17,212,357 · 6
UG3$12,642,705 · 2
UH3$9,466,269 · 2

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Cohort

Research focus

CohortObesityCaliforniaDiabetes MellitusChildAffectWomanRisk FactorsRaceGrowthSamplingPathway InteractionsLife StyleMental DepressionPregnancyMothersDietBirthBody Mass IndexResourcesClinical ResearchEthnic OriginVisitPhysical Activity

Grant awards (42)

Preconception and Prenatal Health Impacting Factors and Child Health$6,495,276
UH3 · FY2025 · OD · contact PI
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$2,970,993
UH3 · FY2025 · OD
Long term adverse health outcomes for women and children following SARS-CoV-2 infection during pregnancy$812,782
R01 · FY2025 · AI · contact PI
Comparing the effects of pharmacological treatment for gestational diabetes on long-term maternal and child health outcomes$672,314
R01 · FY2025 · DK · contact PI
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age$9,288,613
U19 · FY2024 · AG
Preconception and Prenatal Health Impacting Factors and Child Health$4,412,251
UG3 · FY2024 · OD · contact PI
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$3,093,705
UG3 · FY2024 · OD
Long term adverse health outcomes for women and children following SARS-CoV-2 infection during pregnancy$802,563
R01 · FY2024 · AI · contact PI
Comparing the effects of pharmacological treatment for gestational diabetes on long-term maternal and child health outcomes$670,325
R01 · FY2024 · DK · contact PI
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age$249,971
U19 · FY2024 · AG
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$3,112,927
UG3 · FY2023 · OD
Preconception and Prenatal Health Impacting Factors and Child Health$2,023,822
UG3 · FY2023 · OD · contact PI
Long term adverse health outcomes for women and children following SARS-CoV-2 infection during pregnancy$802,700
R01 · FY2023 · AI · contact PI
Impact of Sugary Beverage Taxes on Weight and Health Outcomes after 3-5 Years$707,188
R01 · FY2023 · DK
Cluster randomized trial of a mobile health intervention to achieve appropriate gestational weight gain in overweight/obese women$613,874
R01 · FY2023 · DK · contact PI
Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3$578,966
R01 · FY2023 · GM
Equipment Supplement for Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3$29,371
R01 · FY2023 · GM
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age$10,164,185
U19 · FY2022 · AG
Impact of Sugary Beverage Taxes on Weight and Health Outcomes after 3-5 Years$732,195
R01 · FY2022 · DK
Cluster randomized trial of a mobile health intervention to achieve appropriate gestational weight gain in overweight/obese women$587,915
R01 · FY2022 · DK · contact PI
Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3$585,886
R01 · FY2022 · GM
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age$426,092
U19 · FY2022 · AG
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age$11,145,077
U19 · FY2021 · AG
Impact of Sugary Beverage Taxes on Weight and Health Outcomes after 3-5 Years$722,508
R01 · FY2021 · DK
Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3$599,475
R01 · FY2021 · GM
Cluster randomized trial of a mobile health intervention to achieve appropriate gestational weight gain in overweight/obese women$591,854
R01 · FY2021 · DK · contact PI
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age$315,983
U19 · FY2021 · AG
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age$196,732
U19 · FY2021 · AG
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age$10,998,003
U19 · FY2020 · AG
Impact of Sugary Beverage Taxes on Weight and Health Outcomes after 3-5 Years$743,030
R01 · FY2020 · DK
Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3$624,418
R01 · FY2020 · GM
Cluster randomized trial of a mobile health intervention to achieve appropriate gestational weight gain in overweight/obese women$558,600
R01 · FY2020 · DK · contact PI
Cluster randomized trial of a mobile health intervention to achieve appropriate gestational weight gain in overweight/obese women$647,648
R01 · FY2019 · DK · contact PI
Discovery of Pharmacogenomic Biomarkers for Metformin Response$720,081
R01 · FY2018 · GM
Discovery of Pharmacogenomic Biomarkers for Metformin Response$719,085
R01 · FY2017 · GM
Discovery of Pharmacogenomic Biomarkers for Metformin Response$803,285
R01 · FY2016 · GM
Equipment Supplement due 5/20/2016 P0516422$24,942
R01 · FY2016 · GM
Discovery of Pharmacogenomic Biomarkers for Metformin Response$837,363
R01 · FY2015 · GM
Pregravid biomarkers of GDM risk, fetal growth and progression to diabetes$450,487
R01 · FY2013 · HD · contact PI
Pregravid biomarkers of GDM risk, fetal growth and progression to diabetes$487,498
R01 · FY2012 · HD · contact PI
Pregravid biomarkers of GDM risk, fetal growth and progression to diabetes$541,572
R01 · FY2011 · HD · contact PI
Pregravid biomarkers of GDM risk, fetal growth and progression to diabetes$544,432
R01 · FY2010 · HD · contact PI